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ABSTRACT
Dendritic cells (DC) are antigen-presenting cells involved in induction and regulation of immune responses.We
investigated the impact of the number of infused and day 28 dendritic cells on the development of acute and
chronicGVHD (aGVHD, cGVHD).Monocytoid (MC) and plasmacytoid (PC) dendritic cells were characterized
as lin2HLA-DR1CD11c1 and lin2HLA-DR1CD1231, respectively. Sixty-eight consecutive patients who un-
derwent HLA matched related granuloyte-colony stimulating factor (G-CSF) mobilized allogeneic PBSCT,
from February 2005 to May 2006, were included in the analysis. Twenty-three patients developed aGVHD
(grade II-IV) and 21 patients had cGVHD. On a univariate analysis the day 28 total DC and the day 28 MC
and PC dendritic cells as continuous variables were significantly associated with development of aGVHD and
cGVHD. Using an ROC plot analysis a cutoff value for total DC 5 10.7/mL, MC 5 9.7/mL, and PC 5 4.5/mL
on day 28 gave the highest likelihood ratios for aGVHD (2.7, 2.14, and 3.29, respectively). On amultivariate anal-
ysis, a low day 28 PC (#4.5/mL) together with patient age retained their risk for aGVHD (hazard ratio [HR] 5
65.1 and 1.0, P-values .000 and .036, respectively), whereas for cGVHD only a low day 28 PC remained signif-
icant (HR5 11.8, P5 .008). These results suggest that the PC dendritic cell count in the peripheral blood on day
28 is a strong predictor for development of GVHD in recipients of an allogeneic matched related PBSCT.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Acute GVHD  Chronic GVHD  Plasmacytoid dendritic cell count  GVHD predic-
tion  PBSCTINTRODUCTION
Allogeneic stem cell transplantation (SCT) re-
mains the best therapeutic option for a number of
malignant and nonmalignant hematologic diseases.
Significant obstacles limiting the efficacy of allogeneic
SCT are the occurrence of regimen-related toxicity
(RRT), graft-versus-host disease (GVHD), tumor re-
lapse, engraftment failure, and susceptibility of patients
to opportunistic infections after transplantation [1-4].
Development of both acute and chronic GVHD
(aGVHD, cGVHD) is a major limitation of peripheral
blood SCT (PBSCT), contributing significantly to344morbidity andmortality [5,6]. There are limited robust
predictors ofGVHDafter amatched related allogeneic
PBSCT.
After SCT, immune response is determined early
by both mature immunocompetent cells transferred
within the allograft and by immune cells that develop
de novo from transplanted stem cells. Different cell
lineages reconstitute at different rates, and this could
have an impact on clinical outcomes post transplanta-
tion [7]. Dendritic cells (DCs) are antigen-presenting
cells involved in induction and regulation of immune
responses. DC precursors in blood constitute \1%
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ability to induce naı¨ve T cell differentiation to Th1
and Th2 effector cells, 2 distinct lineages of DCs
have been identified, namely, monocytoid (MC) and
plasmacytoid (PC) DCs, which do not express lineage
markers (CD3, CD14, CD16, CD19, CD20, and
CD56) but are positive for HLA-DR and either
CD11c or CD123 (IL-3 receptor a-chain), respec-
tively [9,10].
Despite a 10-fold higher dose of transplanted T
cells in PBSC recipients compared to marrow recipi-
ents, aGVHD does not develop in a significantly
higher proportion among PBSC recipients as one
would have anticipated based on the T cell dose.
This is attributed to G-CSF selectively mobilizing
PC DCs and the ability of activated PC DCs to prime
T lymphocytes to produce Th2 cytokines that has been
hypothesized to favor immunotolerance [11,12].
We undertook a prospective analysis to study the im-
pactof thenumberof infusedandday28 totalDCandsub-
sets, namely MC (monocytoid, lin-HLA-DR1CD11c1)
and PC (plasmacytoid, lin2HLA2DR1CD1231) DCs,
on the development of aGVHD and cGVHD.
PATIENTS, MATERIALS, AND METHODS
All patients who underwent an allogeneic HLA
matched related PBSCT at our center, between Febru-
ary 2005 and May 2006, were included in this study. A
written informed consent was obtained from all pa-
tients, and in the case of minors, from their parents
or legal guardians. Patients were nursed in rooms
with a positive-pressure HEPA filtered air.
Conditioning
Thirty-four (50%) patients were conditioned us-
ing a conventional myeloablative regimen consisting
of busulphan (16 mg/kg) and cyclophosphamide (120
mg/kg). The rest received a reduced-intensity condi-
tioning (RIC) regimen; in the majority this was fludar-
abine based (Table 1).
Graft Source and Engraftment
Granulocyte-colony stimulating factor (G-CSF)
stimulated PBSCs were collected from the donor
with a target cell dose of 5 108MNC/kg body weight
of the recipient. Neutrophil engraftment was defined
as the first of 3 consecutive days with ANC .0.5 
109/Lt, whereas platelet engraftment was defined as
the first of 3 consecutive untransfused platelet counts
.20  109/Lt. Samples of PBSC harvests and post-
transplant day 28 peripheral blood were obtained in
sodium heparin vacutainer tubes for flowcytometry
analysis.GVHD Prophylaxis
Cyclosporine and short methotrexate was used as
GVHD prophylaxis. Cyclosporine was administered
at a dose of 2.5 mg/kg intravenously over 4 hours twice
daily starting on day24, and changed to oral adminis-
tration at 5 mg/kg twice daily when mucositis had
resolved. Cyclosporine levels were monitored and
the dose adjusted to achieve a target level of 100-300
ng/mL. The methotrexate dose was 10 mg/m2 on
day 1 and 7 mg/m2 on days 3, 6, and 11 (in 5 cases
the day 1 dose was 15 mg/m2 and the day 3, 6, and
11 doses were 10 mg/m2). If mucositis was severe
(grade IV) or bilirubin .20 mg/L, the day 6 and day
11 doses were omitted. Acute GVHD was treated
with dexamethasone or methyl prednisone. Steroid
refractory GVHD was treated as per the discretion
of the treating physician. Patients who died before
day 28 were excluded from DC analysis.
Definition of Outcomes
Incidence and severity of GVHD was defined as
per established criteria [13]. Overall survival (OS)
Table 1. Baseline Characteristics
Characteristics
Value n (%)/median
(range)
Patients —
Males 43 (63.2)
Age (years) 27 (3-55)
Donors —
Males 36 (52.9)
Age (years) 29 (9-63)
Diagnosis —
Acute lymphoblastic leukemia 6 (8.8)
Acute myeloid leukemia 31 (45.6)
Acute undifferentiated leukemia 1 (1.5)
Aplastic anemia 12 (17.6)
Biphenotypic acute leukemia 2 (2.9)
Chronic myeloid leukemia 5 (7.4)
Dyskeratosis congenita 1 (1.5)
Myelodysplastic syndrome 6 (8.8)
Myelofibrosis 2 (2.9)
Paroxysmal nocturnal hemoglobinuria 1 (1.5)
b-Thalassemia major 1 (1.5)
Conditioning regimen —
Myeloablative 34 (50)
Bu/Cy 20 (29.4)
Cy/TBI 14 (20.6)
Reduced intensity 34 (50)
Flu/Mel 12 (17.6)
Flu/Cy 15 (21.1)
Flu/Cy/ATG 3 (4.4)
Flu/Bu/Cy 1 (1.5)
Flu 1 (1.5)
Ida/Flu/Cytosine 2 (2.9)
ATG indicates antithymocyte globulin; Bu, Busulfan; Cy, Cyclo-
phosphamide; Flu, Fludarabine; Mel, Melphalan; TBI, total-
body irradiation.
346 R. Rajasekar et al.was defined as time from initiating treatment to last
follow-up or death. Event-free survival was calculated
from time of initiating therapy to last follow-up or an
event (relapse or death).
DCs Enumeration
DC were enumerated using FITC-conjugated
monoclonal antibodies directed against leukocyte
lineage markers (Lin: anti-CD3, CD14, CD16,
CD19, CD20, CD56, BD Biosciences, San Jose,
CA), PE-conjugated anti-CD11c (BD Biosciences),
PE-conjugated anti-CD123 (BD Biosciences), and
PerCP-conjugated anti-HLA-DR (BD Biosciences).
The whole blood was incubated with appropriate anti-
body combinations (MC 5 Lin, HLA-DR, CD11c,
PC 5 Lin, HLA-DR, CD123) for 15 minutes at
room temperature in the dark followed by red cell lysis
with ammonium chloride. The cells were then washed
twice in phosphate-buffered saline. Events were then
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Figure 1. Mean day-28 PC counts and GVHD.acquired on a FACSCalibur flowcytometer (Becton
Dickenson, Mansfield, MA. Data analysis was per-
formed using CellQuestPro software (Becton Dicken-
son). Dead cells were gated out before the final analysis
using side-scatter/forward-scatter dot-plots. A mini-
mum of 75,000 events were acquired per analysis.
Previously described method for identification and
enumeration of DC subsets was used [14]. Cells nega-
tive for lineage markers (Lin2) were gated and then
analyzed for HLA-DR and CD11c for MC and
CD123 expression for PC. An absolute DC value
(mL) was determined by multiplying the percentage
of MC and PC DCs with the total number of white
blood cells.
Apart from DCs, graft and posttransplant day 28
peripheral blood samples were analyzed for CD34,
CD133, CD3, CD4, CD4CD45RA, CD4CD45RO,
CD8, CD8CD45RA, CD8CD45RO, CD19, and
NK cell (CD161, CD561, CD32) counts.
Statistical Analysis
Statistical analyses were performed with SPSS for
Windows 11.01 version (SPSS Inc., Chicago, IL). c2
and Mann-Whitney U-tests was used for parametric
and nonparametric data, respectively. A receiver operat-
ing characteristic (ROC) curvewas used todesignate the
cutoff level for total DC (sum ofMC and PC), MC and
PCDCcount.The effects ofhigh versus lowday28DC,
MC, and PC count on outcomes were tested using
Kaplan-Meier methods. Log-rank tests were used to
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Figure 2. Predictive sensitivity and specificity testing of day 28 DC,
day 28 MC, and day 28 PC cell count for aGVHD using an ROC
plot.
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Characteristics n (%)/median (range) Low PC (#4.5/mL) (n 5 30) High PC (.4.5/mL) (n 5 31) P-Value
Patient — — —
Males 20 (66.7) 18 (58.1) .600
Age (years) 29 (5- 53) 25 (3-55) .201
Female donor to male recipient 10 (33.3) 11 (35.5) 1.000
Conditioning regimen — — —
Myeloablative 10 (33.3) 22 (71) .005
Graft (106/kg) — — —
CD34 12.5 (3.2-74.2) 12.2 (2.3-44.4) .604
CD133 10.1 (3.9-53) 10.1 (2-42.5) .660
CD3 189 (61.1-403) 166.4 (47.1-515.7) .267
CD19 11.5 (3.4-293.1) 21.8 (1.6-248.5) .141
CD4 116.6 (35.9-256.6) 92.2 (17.9-272.1) .162
CD4CD45RA 43 (10.7-139.3) 31.1 (4.7-132.1) .248
CD4CD45RO 46.3 (18.2-120) 46.4 (12.2-196.3) .624
CD8 79.8 (22.5-212.9) 80.2 (15.6-354.5) .697
CD8CD45RA 45 (11.3-130) 47.2 (12.7-175.3) .593
CD8CD45RO 26.2 (8.4-85.1) 24 (5.2-189.5) .498
CD161CD561CD32 17.7 (2.6-90) 17.1 (4.7-74) .778
MC 0.8 (0.1-2.6) 0.9 (0.2-3.3) .341
PC 2 (0.1-9.6) 2.3 (0.4-14.8) .530
Engraftment (days) – — —
ANC .500/mm3 11.5 (9-18) 14 (10-18) .013
Platelet .20,000/mm3 15 (9-160) 11 (8-39) .004
Day-28 subsets (106/Lt) — — —
CD3 610.4 (11.9-15116.3) 750.4 (297.2-2789.8) .248
CD19 36.3 (1-449.3) 19.8 (1-302) .109
CD4 314.5 (6.7-1670.9) 371.6 (161.6-1926.6) .175
CD4CD45RA 110.1 (3-904.2) 120.3 (35.8-509.7) .267
CD4CD45RO 162.8 (5.7-708.9) 216.6 (82-872.1) .106
CD8 270.7 (7-13226.8) 340.7 (91.1-1663.1) .111
CD8CD45RA 132 (3-1774) 231.9 (40.2-876.4) .017
CD8CD45RO 111.3 (2.1-6308.9) 131.2 (32.2-923.3) .273
CD161CD561CD32 173.5 (24.1-704.8) 230.3 (90.4-542.1) .028
MC 2.4 (0.5-16.9) 16.8 (2.8-151.8) .000
PC 2.1 (0.5-4.4) 14 (4.6-72.6) .000
Acute GVHD (grade (II-IV)) 19 (63.3) 2 (6.5) .000
Chronic GVHD 14 (51.9) 7 (25.9) .093
Survival — — —
Relapse 1 (3.3) 7 (22.6) .053
Death 6 (20) 6 (19) 1.000
MC indicates monocytoid dendritic cell; PC, plasmacytoid dendritic cell.measure significant differences between strata. Cox
models were used to assess the proportional hazards of
various subsets both in the graft and those engrafted
after transplant. To confirm outcomes and to adjustfor potential confounding factors,multivariateCoxpro-
portional hazards models were also done. A probability
type1 error\.05,was considered the thresholdof statis-
tical significance.Table 3.Multivariate Relative Risk (RR) Analysis for GVHD
Acute GVHD Chronic GVHD
Variable RR (95% CI) P-value RR (95% CI) P-value
Patient age 1.0 (1.0-1.09) .036 1.0 (0.98-1.06) .457
Female-to-male transplant 0.4 (0.14-1.45) .179 1.7 (0.68-4.52) .249
Myeloablative Conditioning 2.3 (0.85-6.03) .101 1.9 (0.70-5.36) .205
Day 28 NK cell count 1.0 (1.0-1.0) .415 1.0 (1.0-1.0) .627
Day 28-DC low\10.7/mL 0.1 (0.01-1.52) .105 0.1 (0.02-0.69) .020
Day 28-MC low\9.7/mL 2.1 (0.15-31.27) .570 3.1 (0.61-16.04) .172
Day 28-PC low\4.5/mL 65.1 (7.34-577.06) .000 11.8 (1.89-73.41) .008
DC, Total dendritic cell; MC, monocytoid dendritic cell; PC, plasmacytoid dendritic cell; CI, confidence interval.
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Patient and Graft Characteristics
There were 68 patients (43 men and 25 women)
with a median age 27 years (range: 3-55). The mean
follow-up was 405 days. Patient characteristics are
summarized in Table 1.
DC Count and GVHD
Twenty-three patients developed aGVHD (grade
II-IV) and 21 patients had cGVHD. Seven patients
died before day 28 and were excluded from the analy-
sis; 2 of these patients had aGVHD. The mean abso-
lute day 28 PC DC counts in patients with acute
grade (II-IV) and cGVHD was significantly lower
compared to those who did not develop GVHD (P 5
.000 and P 5 .064, respectively) (Figure 1). When an-
alyzed as continuous variable the day 28 total DC,MC,
and PC DC counts were significantly associated with
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Figure 3. Cumulative incidence of aGVHD by day 28 PC.
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Figure 4. Cumulative incidence of cGVHD by day 28 PC.development of aGVHD, whereas graft total DC,
MC, and PC DC counts did not show a similar associ-
ation.
Using ROC curve analysis, cutoff values (day 28
total DC 5 10.7/mL, MC 5 9.7/mL, and PC 5 4.5/
mL), which gave the highest likelihood ratios for
aGVHD (2.7, 2.14, and 3.29, respectively), was deter-
mined (Figure 2). The area under the curve for PC
(0.830) was higher when compared to total DC
(0.759) and MC (0.712). These cutoff values signifi-
cantly discriminated patient’s probability of develop-
ing aGVHD and cGVHD on a univariate analysis.
Using the PC DC count cutoff value of 4.5/mL,
patients were categorized into a high (.4.5/mL) (n 5
31) and a low (#4.5/mL) (n 5 30) day 28 PC level
groups. These 2 groups were comparable with regard
to age, sex, female-to-male transplants, and graft char-
acteristics (CD34,CD133,CD3,CD4,CD4CD45RA,
CD4CD45RO, CD8, CD8CD45RA, CD8CD45RO,
CD19, NK, MC, and PC cell dose) as shown in Table
2. However, significantly more cases in the day 28 high
PC group received a myeloablative conditioning regi-
men. Twelve of 61 of our patients received steroids
before day 28 for treatment of GVHD. We excluded
these patients to see the effect of steroids on DCs.
Low day 28 PC (#4.5 cells/mL) still retained its signif-
icance for development of aGVHD (relative risk
[RR] 5 5.1 (95% confidence interval [CI] 1.06-
24.50), P 5 .042).
On a multivariate analysis, a low day 28 PC (#4.5/
mL), together with patient age, retained their risk for
aGVHD (HR 5 65.1 and 1.0, P-values .000 and
.036, respectively), whereas for cGVHD only a low
day 28 PC remained significant (HR 5 11.8, P 5
.008) (Table 3). Cumulative incidence of aGVHD
and cGVHD compared by log-rank test revealed that
the low PC group had a significant risk (P 5 .000
and .006, respectively) of developing aGVHD and
cGVHD (Figures 3 and 4).
These results suggest that the day 28 PC count in
the peripheral blood is a strong predictor for develop-
ment of aGVHDand cGVHDin recipients ofmatched
related allogeneic PBSCT.
DISCUSSION
We hypothesized that graft DC count and early
postengraftment DC counts would have an important
impact on development of aGVHD and cGVHD,
given the central role for DC in the immune response.
DC process and present both endogenously and exog-
enously derived antigens. Therefore, in the setting of
a major histocompatibility complex matched alloge-
neic SCT procedure, DC arising from the donor graft
and DC persisting from recipients are expected to
present endogenous minor donor antigen peptides
that will influence T cell activation and/or induction
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shown the central role of host DC in recipient antigen
presentation to donor T cells that could potentially
induce GVHD. Recipient DC are radioresistant and
can survive pretransplant conditioning regimens that
target cycling or proliferating cells. Persistent host
DC can function as initiators, as well as be targets of
GVHD reactivity against minor antigens [17]. It has
been demonstrated that both residual host and en-
grafting donor APCs contribute to development of
GVHD [16,18]. Our chimerism analysis (peripheral
blood MNC by VNTR analysis) done routinely for
all transplants on day 28 showed a complete chimera
in 90.6% (48 of 53 cases). Althoughwe did not perform
a DC subset chimerism on the day 28 samples, from
the chimerism data it is likely that the measured PC
DCs are donor in origin. It has also been noted that
both in myeloablative and RIC the majority of the cir-
culating DCs are of donor origin even in the presence
of mixed chimerism in other lineages, including T cells
[19,20].
Acute GVHD is usually first treated with cortico-
steroids. Earlier studies have shown that use of cortico-
steroids leads to decreased bloodDC in various human
disorders, including GVHD [14,18,21]. Nine of the 21
patients who developed aGVHD did not receive ste-
roids before day 28 for treatment. Their day 28 PC
count was significantly lower than the group that did
not develop GVHD, although not significantly differ-
ent from the group that received steroids (data not
shown). Even after excluding patients who received
steroids prior to day 28 (12 patients), a low day 28
PC count retained its statistically significant associa-
tion with the development of aGVHD.
Our categorization of low and high PC patient
groups were comparable with regard to recipient age,
sex, graft characteristics (CD34, CD133,CD3, CD4,
CD4CD45RA, CD4CD45RO, CD8, CD8CD45RA,
CD8CD45RO, CD19, NK, MC, and PC cell dose)
and engrafted T and B cells (Table 2). The groups
were significantly different in the numbers that re-
ceived a myeloablative conditioning regimen and in
the number of NK cells in the peripheral blood on
day 28. However, neither of these parameters was sig-
nificantly associated with GVHD in a univariate anal-
ysis and adjusting for these factors in a multivariate
analysis, the day 28 PC count still retained its statisti-
cally significant association with GVHD. DC cutoff
values obtained in this study were comparable to that
stated previously [22]. Identifying potential causes of
low peripheral blood PC counts after SCT among
those who develop a GVHD and cGVHD needs fur-
ther investigation. It has been suggested that PCmight
have homed to lymphoid tissues or target organs of
GVHD because of allogeneic stimuli or alternatively
with the onset of GVHD there is conversion of PC
to MC DCs [16].Waller et al. [23] suggested that donor DC content
in the bone marrow graft before transplantation had an
impact on clinical outcomes after bone marrow trans-
plantation. In our analysis we were unable to show
a similar association with graft DC count. Our obser-
vations were consistent with data previously reported
by Reddy et al. [22], which suggested that in patients
under going a PBSCT the number of DC in the graft
has no impact, whereas the number of DC that recon-
stituted in the recipient early after a transplant ap-
peared to have an impact on the incidence of GVHD
and the clinical outcome post transplant.
Recently it was reported that activated circulating
DC after a hematopoietic SCT predicts aGVHD and
a DC activation marker CMRF-44 was found to be
most informative in predicting onset of GVHD [24].
However, in this study as well it was noted that patients
with aGVHD (grade II-IV) had a significantly lower
level of MC and PC DC count compared to those
that did not develop aGVHD [24].
Our data suggests that early post engraftment cir-
culating PC DC count after an allogeneic hematopoi-
etic SCT is an independent predictor for development
of aGVHD and cGVHD. Enumerating absolute PC
DC count as reported in our study may be a simple,
fast, and reproducible method to predict development
of aGVHD and cGVHD after PBSCT. Based on the
day 28 PC DC counts, it would potentially be possible
to stratify patients into risk groups for developing
GVHD and further stratify them for therapeutic inter-
ventions to enhance or negate the impact of GVHD.
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